Thursday broker round-up
21st May 2015 13:01
Barclays: JP Morgan Cazenove reiterates overweight and 285p target. StanChart: Goldman sachs reiterates neutral. St.James Place: Numis reiterates add and 1050p target. Hargreaves Lansdown: JP Morgan Cazenove reiterates neutral and raises target to 1,100p from 1,050p. UK Mail Group: RBC Capital re
Read moreThursday broker round-up
14th May 2015 14:30
ITV: Numis downgrades to add but nudges target to 290p from 275p, Investec reiterates hold and Credit Suisse reiterates outperform. SAB Miller: Credit Suisse reiterates underperform stance, Nomura reiterates neutral recommendation and Deutsche reiterates its call to hold. GlaxoSmithKline: UBS downg
Read moreFTSE 100 movers: ITV hit by strike and stiff BBC competition, miners lower
14th May 2015 12:56
UK stocks rebounded from early losses, but remained restrained by concerns of Greek instability. Sector wise, miners and technology services provided the biggest drag, while insurers and utilities gave a welcome boost. At 1:45 BST, the FTSE 100 was trading 12 points higher at 6,962. ITV declined a
Read moreWednesday broker round-up
13th May 2015 13:13
BHP Billiton: Credit Suisse reiterates underperform and 1,400p target, UBS stays at buy with 1,625p target. Experian: Nomura reiterates buy and nudges target higher to 1,265p from 1,230p, Exane BNP keeps at neutral with 1,200p target. Talk Talk: UBS hikes target to 350p from 300p and reiterates neu
Read moreMonday broker round-up
11th May 2015 15:36
RBS: Credit Suisse reiterates underperform and 320p target. GlaxoSmithKline: Deutsche reiterates hold and lowers target to 1,540p from 1,600p. HSBC: Exane BNP reiterates underperform and 600p target. Lloyds: Credit Suisse reiterates neutral and 72p target. Sage Group: Goldman Sachs reiterates neu
Read moreThursday tips round-up: GlaxoSmithKline, Sage
7th May 2015 16:53
GlaxoSmithKline's decision not to proceed with the sale of part of its HIV unit, announced as part of its strategy update on 6 May, was the right one. It would pocket $10bn from such a sale but the unit is also the source of the quickest revenue growth at the company, with sales up 15% last year. Th
Read moreThursday broker round-up
7th May 2015 16:39
Morrison: Shore Capital reiterates buy. Direct Line Insurance Group: Canaccord Genuity reiterates buy and 350p target. BAE Systems: Charles Stanley reiterates accumulate. GlaxoSmithKline: UBS reiterates buy and 1,700p target. Aviva: Panmure Gordon reiterates buy and raises target to 660p from 600
Read moreGSK cuts Novartis payout as first-quarter revenues rise but earnings ease
6th May 2015 12:32
GlaxoSmithKline posted a modest increase in first-quarter revenue on Wednesday, up 0.2% to £5.62bn from £5.61bn, as the company said it plans to cut the amount of money it will return to shareholders under an asset swap with Novartis. Core operating profit was down 14% on a constant exchange rate ba
Read moreWednesday preview: GSK and Sainsbury's top the bill amid earnings influx
5th May 2015 16:19
While investors will continue to look ahead to the elections, Wednesday's session is set to be a busy one for UK markets amid a barrage of blue-chip corporate earnings and economic data. Glaxosmithkline, Sainsbury's, Sage, Intu Properties, CRH, Direct Line, Legal & General and Boohoo.com are all exp
Read moreTuesday broker round-up
5th May 2015 14:59
Lloyds: Exane, UBS and Jefferies reiterated their buy recommendation, with the latter bumping up its price target to 201p from 88p. BT Group: Credit Suisse reiterates outperform and Barclays its overweight stance, with price targets of 495p and 600p, respectively. Aviva: Barclays ups target to 632p
Read moreGSK expected to can capital return plan amid stagnant growth
1st May 2015 13:10
GlaxoSmithKline may throw out a plan to return £4bn to shareholders amid an overhaul of the drugmaker and a new chairman, analysts have said. Goldman Sachs and Berenberg Bank believe GSK could instead use cash flowing from its asset swap deal with Novartis to support its dividend. Last year GSK sai
Read moreLondon open: Lloyds beats forecasts but markets fall ahead of long weekend
1st May 2015 09:05
London stocks fell on Friday despite a better-than-expected first quarter from Lloyds Banking Group as investors were treading carefully in the absence of trading across Europe. The FTSE 100 was down 0.51% at 6,924.94 early on, with most equity markets on the continent closed for May Day. Analyst C
Read moreGlaxo and Theravance win FDA approval for Breo asthma treatment
1st May 2015 07:54
Glaxosmithkline (GSK) has said its Breo once-daily treatment for adult asthma has been approved by the US Food and Drug Administration (FDA). Breo, developed with US pharmaceutical group Theravance, is a "fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate (FF) and the lon
Read moreWednesday broker round-up
29th Apr 2015 19:53
Sky: JP Morgan reiterates neutral stance and 1,170p target. GlaxoSmithKline: UBS reiterates buy and 1,700p target. StanChart: Nomura reiterates neutral and lifts target to 1,170p from 1,030p. UBS reiterates neutral stance with 1,000p target. Henderson Group: Citi reiterates buy with 3,250p target.
Read moreThursday broker round-up
16th Apr 2015 13:42
AstraZeneca: Societe Generale reiterates buy and 6,660p target price. Tesco: Nomura reiterates neutral and lowers target to 185p from 190p. Burberry: UBS reiterates neutral stance and lifts target to 1,800p from 1,650p. Royal Dutch Shell: Barclays reiterates overweight. Persimmon: Shore Capital r
Read more